Newsmeme!
Discover News you didn't know existed
Agonist
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Schering-Plough announces phase II and III data for corifollitropin alfa
Published July 2, 2009, 9:48 pm, PharmaBiz
Schering-Plough Corp., announced results from the phase III Engage clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.
XenoPort Reports Positive Results From A Phase 2 Trial Of Arbaclofen Placarbil In Spinal Cord Injury Patients With ...
Published July 2, 2009, 7:08 am, Medical News Today
XenoPort, Inc. (Nasdaq:XNPT) announced positive preliminary results from a Phase 2 clinical trial of arbaclofen placarbil (AP), also known as XP19986, for the treatment of patients with spasticity due to spinal cord injury (SCI). Doses of 20 and 30 mg of AP, given twice daily (BID), demonstrated statistically significant improvements compared to placebo for the primary endpoint of the study.
Latest Guidance Issued by BTS/SIGN Supports use of Single Inhaler for Maintenance and Relief in Asthmatic Patients
Published July 2, 2009, 5:00 am, PR Newswire via Yahoo! Finance
Updated guidelines issued this week by the British Thoracic Society and Scottish Intercollegiate Guidelines Network include the use of budesonide/formoterol in a single inhaler as rescue medication, in addition to its regular use as controller therapy, in selected adult patients poorly controlled at step 2 or selected adult patients with poorly controlled asthma at step 3.
My Pharmiweb.com
Published July 2, 2009, 3:49 am, PharmiWeb
AMSTERDAM, THE NETHERLANDS , July 1, 2009 -- Schering-Plough Corp ., (NYSE: SGP) today announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.
Parkinson's Disease Alters Patient's Ability To Learn From Rewards While Treatment Affects Ability To Learn From ...
Published July 2, 2009, 3:09 am, Medical News Today
A new neuropsychological memory test is helping to uncover how Parkinson's disease can alter people's ability to learn about the consequences of the choices they make. The test was developed by Dr. Mark Gluck, professor of neuroscience at the Center for Molecular and Behavioral Neuroscience at Rutgers University, Newark, working with co-researchers at Rutgers, New York University, and in Hungary.
Theravance Announces New Employment Inducement Awards
Published July 1, 2009, 5:33 pm, Marketwire
SOUTH SAN FRANCISCO, CA--(Marketwire - July 1, 2009) - Theravance, Inc. ( NASDAQ : THRX ) today reported that equity awards were made to three new employees. Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), the equity awards were granted under the Theravance, Inc. 2008 New Employee Equity Incentive Plan, which the Board of Directors of Theravance adopted to facilitate the granting of ...
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
Published July 1, 2009, 6:00 am, PR Newswire via Yahoo! Finance
dose of investigational sustained follicle stimulant achieves similar efficacy to daily injections of follitropin beta given over a one week period in Phase III Study
Cardioxyl Pharmaceuticals Initiates Phase I/IIa Study in Heart Failure
Published July 1, 2009, 5:50 am, Marketwire
Study to Evaluate the Safety and Tolerability of Lead Candidate, CXL-1020, in the Treatment of Cardiovascular Disease
My Pharmiweb.com
Published July 1, 2009, 5:49 am, PharmiWeb
LONDON, 26 June, 2009 Merck Sharp & Dohme Limited (MSD), today received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) recommending restricted first line use of 'Januvia' (sitagliptin) for the treatment of type 2 diabetes.
Impaired Decision-Making Fosters Depression In Parkinson’s
Published July 1, 2009, 5:02 am, Psych Central
A new neuropsychological memory test may help explain why many Parkinson’s disease patients develop depression. The test helps to understand how Parkinson’s disease can alter people’s ability to learn about the consequences of the choices they make. Test developer Dr. Mark Gluck found that nonmedicated patients in the early stages of Parkinson’s were selectively [...]
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |